alexa Patient Demographics, Perioperative Testing, and Symptom Management in Total Pancreatectomy with Islet Autotransplantation: A Brief Review | Open Access Journals
ISSN: 2161-1076
Surgery: Current Research
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Patient Demographics, Perioperative Testing, and Symptom Management in Total Pancreatectomy with Islet Autotransplantation: A Brief Review

Claire L. DeBolt1#, Joshua S. Jolissaint1#, Jacob A. Tatum1, Daniel S. Strand2, Andrew Y. Wang2, Victor Zaydfudim1, Reid B. Adams1and Kenneth L. Brayman1*
1Department of Surgery, University of Virginia Health System, Charlottesville, Virginia
2Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia
#Authors contributed equally
*Corresponding Author : Kenneth L. Brayman, M.D., Ph.D
Department of Surgery, University of Virginia Health System
Box 800709, 1215 Lee Street, Charlottesville
22908, Virginia
Tel: (434) 924-9370
Fax: (434) 924-5539
E-mail: klb9r@virginia.edu
Received February 23, 2016; Accepted March 11, 2016; Published March 09, 2016
Citation:DeBolt CL, Jolissaint JS, Tatum JA, Strand DS, Wang AY, et al. (2016) Patient Demographics, Perioperative Testing, and Symptom Management in Total Pancreatectomy with Islet Autotransplantation. Surgery Curr Res 6:264. doi:10.4172/2161-1076.1000264
Copyright: © 2016 DeBolt CL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Surgery: Current Research

Abstract

Background Chronic pancreatitis and its resultant pain, glandular dysfunction, and detriment to quality of life is a challenging and resource-intensive problem for health care systems despite the plethora of modalities developed to treat it. Removal of the gland and source of pain via total pancreatectomy is an effective, albeit drastic solution, with the potential for morbidity due to the complete loss of endocrine and exocrine function. The consequent “brittle diabetes” due to loss of endocrine function and glucagon-dependent counter-regulation may be ameliorated by autologous islet transplantation. Unfortunately, factors leading to optimal outcomes are poorly defined. Results Data is mixed and limited to case series from institutions currently performing the procedure, but factors predictive of islet cell yields and overall insulin-independence include: disease etiology, metabolic status, and duration and severity of the disease. Imaging studies may prove an appropriate method for determination of pancreatic volume and disease complications prior to operative intervention. Although potentially overlooked, the resultant malabsorptive diarrhea, traditionally treated with pancreatic enzyme replacement therapy, is a significant barrier to postoperative quality of life and still requires further research and investigation. Discussion T otal pancreatectomy with autologous islet transplantation is a proven and effective method for treating those with intractable pain from chronic pancreatitis, but remains barred from widespread use due to cost, limited availability, and potential morbidity. Though great advances have been made, additional efforts at perioperative optimization, appropriate candidate selection and time to intervention must still be sought to further improve post-operative outcomes.

Keywords
Pancreatitis; Chronic; Pain management; Pancreatectomy; Pancreaticojejunostomy;Transplantation; Autologous
Abbreviations
BSA: Body Surface Area; CP: Chronic Pancreatitis; CT: Computed Tomography; FSIVGTT: Fasting Sample Intravenous Glucose Tolerance Testing; HbA1c: Glycosylated Hemoglobin A1c; IAT: Islet Autotransplantation; IEQ: Islet Equivalent; IEQ/kg: Islet Equivalent per kilogram Recipient Body Weight; MMTT: Mixed Meal Tolerance Test; SMRCP: Secretin-enhanced Magnetic Resonance Cholangiopancreatograophy; MRI: Magnetic Resonance Imaging; PERT: Pancreatic Enzyme Replacement Therapy; ROC: Receiver Operating Characteristic; TP: Total Pancreatectomy; TPIAT: Total Pancreatectomy with Islet Autotransplantation; QoL: Quality of Life
Introduction
Chronic pancreatitis (CP) is a debilitating condition characterized by progressive pancreatic inflammation, impairment of endocrine and exocrine function, abdominal pain, reduced Quality of Life (QoL), and increased health resource utilization [1,2]. Although patients can be managed with lifestyle changes, medical and endoscopic intervention, and neural blockade, surgical therapy is occasionally indicated for severe disease [3]. For patients without a single anatomical cause or disease refractory to prior operative interventions, total pancreatectomy (TP) provides definitive treatment and substantial long-term pain relief [4]. First employed in 1977 at the University of Minnesota, islet autotransplantation (IAT) has been employed to preserve β-cell function and combat the “brittle diabetes” resulting from the loss of both endocrine function and glucagon-dependent counter-regulation [5]. Although there is substantial potential benefit and demonstrated improved long-term outcomes, outcomes, such as insulin and narcotic independence are variable (Table 1) and perioperative and patientrelated factors associated with ideal outcomes are poorly defined.
Factors predicting outcomes
Information regarding the outcomes of patients undergoing total pancreatectomy with islet autotransplantation (TPIAT) is limited primarily to retrospective case series which have demonstrated correlations between islet yield (in islet equivalents [IEQ] and islet equivalents per kilogram of recipient body weight [IEQ/kg]), lower body surface area (BSA [m2]), and female gender [4,6-8]. Large series have reported significantly higher islet yields in pediatric patients, possibly related to a decreased number of prior surgical interventions which are independently associated with higher rates of islet graft failure 1 year post-operatively [6].
The etiology of CP is variably predictive, and patients with alcoholism or hereditary pancreatitis may have lower pancreas volumes, increased pancreatic structural changes, lower islet yields, and increased risk of islet graft failure, while those with idiopathic may have lower risks of islet graft failure [6,9,10]. Multiple studies have also demonstrated the relationship between longer disease duration and duration of narcotic use with low islet yield and graft failure (Table 2) [6,11]. Perhaps more subjectively, patients who reported more severely impaired physical health prior to surgery also had independently associated increased risk of islet graft failure and higher risk of impaired health at 1 year after TPIAT [6].
Metabolic testing
Metabolic testing prior to surgery is often performed to establish a preoperative baseline for islet function and data suggest fasting glucose levels <100 mg/dL, C-peptide ≥4 ng/mL are associated with higher islet yields, and hemoglobin A1c (HbA1c) and mixed meal tolerance tests (MMTTs) are inversely correlated with IEQ/kg [10-12]. Moreover, fasting sample intravenous glucose tolerance testing (FSIVGTT) and MMTTs have been reported as significant predictors of islet mass ≥2500 IEQ/kg [10]. However, data is inconclusive and other studies have failed to identify significant correlations between total islet yield and perioperative with HbA1c, C-peptide, or glucose levels [13,14].
Pre-operative imaging
Pancreas weight and gross fibrosis are correlated with lower islet yield and both factors negatively impact islet mass, however, these features are usually only determined intra-operatively [10,15]. Preoperative imaging may be used to better predict islet function, IEQ yield, and post-operative outcomes. MRI and computerized tomography (CT) scanning can generate 3-dimensional images of the pancreas and accurately calculate the volume of the pancreas, as well as assess for the presence of structural changes including: parenchymal calcifications, atrophy, and dilation of the main pancreatic duct. Islet yield has been understandably correlated with increased pancreatic mass, and mean islet yield has been reported to be decreased by 50% if any structural changes are demonstrated on imaging [9]. Calcifications in particular increase the odds of insulin dependence greatly, with only 15% of those with calcifications being insulin independent 1-year postoperatively [9]. Additionally, utilizing magnetic resonance imaging (MRI) and secretin-enhanced magnetic resonance cholangiopancreatography (SMRCP), features such as T1 signal-intensity ratio between the pancreas and paraspinal muscles and duodenal filling after secretin injection can accurately predict pancreatic fibrosis, islet mass, and subsequent islet yield [10,16].
Pancreatic enzyme replacement therapy (PERT)
Although pancreatic enzyme replacement therapy (PERT) is routinely employed to counteract the loss of exocrine pancreatic function, patients continue to experience symptoms related to gastrointestinal malabsorption, including steatorrhea, weight loss, and glycemic variability. One study of 184 patients revealed that, 80% of individuals reported diarrhea 1-year postoperatively and half felt that it interfered with their daily life [17]. In the same study, 72% of patients felt that their steatorrhea had increased significantly by 3-years postoperatively, however, the use of pancreatic enzymes was only marginally associated with decreased likelihood of steatorrhea (OR 0.35, 95% CI 0.12- 1.06, p = 0.055) [17]. Additionally, there was no significant association between increased GI symptoms and decreased (self-reported) adherence to pancreatic enzyme replacement therapy (PERT) (p = 0.7) [17].
Discussion and Conclusions
There are still many barriers that limit the utility and outcomes of TPIAT and only a few highly experienced centers available are available to perform the operation. Insurance companies are often reluctant to cover the costs of islet isolation and many physicians are unfamiliar with the procedure or post-operative anatomy, physiology, or imaging, thus requiring patients to return to the TPIAT center for care and potentially resulting in delayed or absent follow-up [18,19].
Predictive factors suggest that when deciding on timing for TPIAT, delaying surgery is likely disadvantageous, as the duration of CP and worsening metabolic status are predictive of higher rates of graft failures and as more severely impaired patients are not likely to reach a normal state postoperatively. Factors suggestive of good outcomes should not necessarily limit patient selection but rather, should permit multidisciplinary health teams to assess candidacy and thereby provide appropriate pre-operative counseling and improved post-operative care, while still acknowledging and preparing for those at risk for poor outcomes.
Ultimately, TPIAT has proven benefit, with preservation of β-cell function and pancreas removal often resulting in insulin independence drastically improved QoL. However, there are still many questions to be addressed, including appropriate timing for TPIAT intervention, best practice for islet isolation and transplantation, and how to manage post-operative pain and gastrointestinal complications. With continued research into each facet of pre- and postoperative care, in addition to improved insight into optimal patient selection, TPIAT is a procedure adequately poised to address the CP as a societal healthcare burden and improve quality of life for patients.
Disclosures
Andrew Y. Wang, M.D., receives research support from Cook Medical regarding metal biliary stents
References

Tables and Figures at a glance

Table icon Table icon
Table 1 Table 2
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 7877
  • [From(publication date):
    March-2016 - Mar 30, 2017]
  • Breakdown by view type
  • HTML page views : 7836
  • PDF downloads :41
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version